Portal de Periódicos da CAPES

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

2016; Elsevier BV; Volume: 129; Issue: 2 Linguagem: Inglês

10.1182/blood-2016-10-745133

1528-0020

Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Raman, Bao Nguyen, Donald Small, Mark J. Levis,

Myeloproliferative Neoplasms: Diagnosis and Treatment

To the editor: FLT3-activating mutations are one of the most frequent genetic aberrations in acute myeloid leukemia (AML).[1][1] Internal tandem duplication (FLT3-ITD) mutations are associated with the worst prognosis, whereas tyrosine kinase domain (FLT3/TKD) mutations have an uncertain prognostic